liver disease news and health articles

Friday 10 October, 2008
coming soon...
Khichadi Recipe
Calorie Intake & BMI calculator
Convert pounds to kilograms

Health related products & services:

liver disease news and health articles

See also : Alternative medicine news | Alzheimers news | back pain news | Cancer news | Latest depression News | Diabetes news | Diet news | Exercise and fitness news | Healthy eating news | Vitamin news


10/10/2008 08:00 AM
  • Genelabs Announces Presentation Of Data On Non-Nucleoside HCV Polymerase Inhibitor At International Symposium On Hepatitis C Virus And Related Viruses
  • Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three presentations were made at the 15th International Symposium on Hepatitis C Virus and Related Viruses, each on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs. The presentations focused on the discovery, in vitro antiviral activity, resistance profile, pharmacokinetics and mechanism of action of GL60667 (NVP-LDI133), a potent non-nucleoside inhibitor of the HCV NS5B polymerase.
    10/09/2008 03:00 AM
  • RNA Molecules, Delivery System Improve Vaccine Responses, Effectiveness
  • A novel delivery system that could lead to more efficient and more disease-specific vaccines against infectious diseases has been developed by biomedical engineers at The University of Texas at Austin.
    10/08/2008 12:00 PM
  • Why Should Prednisolone Suppress Hepatic Ischemia-Reperfusion Injury?
  • Hepatic ischemia-reperfusion injury is a serious complication but unavoidable problem in liver surgery including liver transplantation and hepatic resection. The most important consequence of this pathological process is multiple organ failure with a high mortality rate.
    10/08/2008 12:00 PM
  • What Is The Pathogenesis Of Liver Damage Induced By Ethanol?
  • They investigated the effects of ethanol on the IGF-I system with the involvement of JNK1/2 activity and ADH by using each chemical inhibitor in primary cultured rat hepatocytes. The results indicate that ethanol inducedp-JNK1/2 activation is associated with the IGF-I system and cell viability in hepatocytes. Furthermore, alcohol dehydrogenase is involved in the relationship between ethanol-induced inactivation of p-JNK1/2 and the changes of the IGF-I system and cell viability.
    10/08/2008 08:00 AM
  • Gut Reaction To Arsenic Exposure Simulated By Scientists
  • A simulated gastrointestinal system is helping scientists test contaminated soil for its potential to harm humans. The method is likely to save time and money for people hoping to repurpose land with an industrial past. Most testing for potential arsenic exposure is conducted in recognition of a dirty little secret of modern life: Humans unknowingly eat a little bit of soil each day.
    10/07/2008 11:00 AM
  • Rifaximin Demonstrates Highly Statistically Significant Results In Prevention Of Hepatic Encephalopathy In Pivotal Phase 3 Study
  • Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of its pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of rifaximin in preventing hepatic encephalopathy, or HE. This study demonstrates that the protocol-specified, intent-to-treat, primary endpoint comparison of a 6-month course of rifaximin at 550 mg dosed twice-a-day provides a highly statistically significant result in preventing HE, compared to placebo.
    10/07/2008 10:00 AM
  • Vitamin D Deficiency Common In Patients With IBD, Chronic Liver Disease
  • Vitamin D replacement may be necessary to reverse deficiency-related bone loss New research presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found patients with inflammatory bowel disease or chronic liver disease were at increased risk of developing Vitamin D deficiencies. Two separate studies highlight the importance of regular Vitamin D checkups in the evaluation of patients with certain digestive diseases.
    10/07/2008 06:00 AM
  • Treating Unresectable Liver Metastases From Melanoma - Investigator Presents On Delcath Systems Phase III Trial Experience
  • Delcath Systems, Inc. (NASDAQ: DCTH) reported that the Adjunct Principal Investigator for its Phase III clinical trial, James Pingpank, Jr., MD, discussed interim results from its randomized study of high-dose melphalan, delivered via the Company's Percutaneous Hepatic Perfusion (PHP) system, in patients with inoperable liver metastases from melanoma. Dr.
    10/06/2008 03:00 AM
  • StemCells, Inc. Receives NIH Grant To Pursue Cell-Based Therapeutic For Hepatitis C
  • StemCells, Inc. (Nasdaq:STEM) announced that it has been awarded a $305,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to research and develop a potential cell-based therapeutic for liver disease arising from infection by the hepatitis C virus (HCV). Hepatitis C is a global health challenge, with approximately 170 million people affected worldwide and an estimated three million new infections each year.
    10/03/2008 06:00 AM
  • Liver Transplant Recipients Almost 3 Times More Likely To Develop Cancer
  • Cancer incidence is higher among liver transplant recipients in Finland compared to the general population, according to a new study in the October issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online at Wiley Interscience (http://www.interscience.wiley.com/).
    10/03/2008 02:00 AM
  • Liver Disease On The Rise, But New Treatments Coming
  • It's another result of an aging baby boom population: an upsurge in cases of liver cancer and other forms of liver disease caused by years of chronic infection with a virus many people don't even realize they have. Fortunately, scientists at an upcoming international conference will report that improved ways of stopping hepatitis C are on the horizon. Approximately 3.
    09/30/2008 04:00 AM
  • Risk For Pancreatic Cancer May Be Increased By Hepatitis B Exposure
  • In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer. The study, published in the Oct. 1 edition of the Journal of Clinical Oncology, also suggests that patients with this lethal form of cancer treated with chemotherapy may face danger of reactivation of their HBV.
    09/28/2008 10:00 AM
  • Successful Construction Of Eukaryotic Plasmids Containing HBV C Genotype
  • HBV infection remains a major health problem in the world. Several data have revealed that lamivudine can efficiently promote the treatment of hepatitis B. However, a long-term treatment of lamivudine leads to the emergence of lamivudine-resistant mutants (YMDD mutants), which hampers the anti-HBV therapy. Therefore, researches related to HBV lamivudine-resistant mechanism has been of great significance.
    09/26/2008 07:00 AM
  • A Novel Therapy For Bleeding Gastric Varices
  • Two patients with the diagnosis of liver cirrhosis and portal hypertension related to hepatitis infection were admitted to Shanghai Ruijin hospital due to recurrent melena and hematemesis. Isolated gastric varices were observed in the gastric fundus during the retroflexion of gastroscope.
    09/26/2008 06:00 AM
  • The Majority Of Children Vaccinated Against Hepatitis B Are Not At Increased Risk Of MS
  • The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the age of 16. A total of 24.
    09/26/2008 05:00 AM
  • Gene Variant Boosts Risk Of Fatty Liver Disease, UT Southwestern Scientists Discover
  • Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation. They also found that Hispanics are more likely to carry the gene variant responsible for higher liver-fat content than African-Americans and Caucasians.
    09/26/2008 02:00 AM
  • New Hope For Patients With Advanced Liver Disease
  • While there are many causes of advanced liver disease, fatty liver, or NASH (nonalcoholic steatohepatitis), has become the second leading cause of liver transplant in the United States. Obesity, along with elevated cholesterol and diabetes, has long been known to cause increased fat stores, which may be injurious to the liver. Such was the case in Sonny B., a patient at Atlanta Health Institute.
    09/25/2008 11:00 AM
  • Key SVR Data In Treatment-Naïve And Treatment-Failure Genotype 1 HCV Patients, And Clinical Data Exploring Twice-Daily Dosing Regimens
  • Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 31 - November 4, 2008 in San Francisco.
    09/25/2008 10:00 AM
  • An Effective Strategy For Inhibition Of Cirrhosis
  • In China, the incidence of liver cirrhosis is still high, although new therapeutic approaches have recently been proposed, there is no established therapy for liver fibrosis, and Authors investigated the prevention effects of Chinese Medicine Qianggan-Rongxian Soup on liver fibrosis induced by DMN in rats. Chinese Medicin Qianggan-Rongxian decoction can inhibit hepatic fibrosis resulted from chronic liver injury, retard the development of cirrhosis, and notably ameliorate the liver function.
    09/25/2008 10:00 AM
  • Celsion Provides Update On Its Global Pivotal Phase III Primary Liver Cancer Trial
  • Celsion Corporation (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned.
    09/25/2008 09:00 AM
  • Chinese Officials Announce Stricter Punishment For Contaminated Blood Sales
  • The Supreme People's Court and the Supreme People's Procuratorate of China recently released details of a new law regarding illegal blood sales, which state that any agent collecting or supplying blood that causes at least five people to become infected with HIV/AIDS, hepatitis B, hepatitis C or syphilis could face a sentence of 10 years to life in prison, the
    09/25/2008 06:00 AM
  • Selecting Anti-Hepatitis B Virus Agents For Drug-Resistance Patients
  • HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma. The principal treatment for chronic hepatitis B (CHB) involves the use of interferon alpha (IFN-a) or nucleoside analogs.
    09/25/2008 02:00 AM
  • Anadys Pharmaceuticals Announces Successful Outcome Of ANA598 Healthy Volunteer Study And Finalization Of Study Design For Phase Ib Trial In HCV
  • Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary results of a Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported.
    09/24/2008 02:00 PM
  • What Is The Energy Consuming Style In Chronic Severe Hepatitis B Patient Normality?
  • The liver plays a pivotal role in fuel and energy metabolism. Many studies have shown that patients with liver cirrhosis have nutrient and energy metabolism imbalances, which lead to malnutrition and can seriously affect their prognosis. However, the characteristics of the fuel and energy metabolism in patients with chronic severe hepatitis are not clear. A research article published in the World Journal of Gastroenterology addresses this question.
    09/24/2008 02:00 PM
  • The Effect Of Curcuma Wenyujin On Human HepG2 Cancer Cells
  • Hepatocellular carcinoma (HCC) is the fifth most common cancer with more than 1 million fatalities occurring annually worldwide. Nowadays in China, the essential oil of Curcuma wenyujin (CWO) has been used as an injection to cure paediatric diseases such as acute upper respiratory infections, viral myocarditis and acute pneumonia. The inhibitory effects of CWO on the SMMC-7721 cell line, cervical cell, L615 cell and K562 cell line growth have been reported.

    See also: Latest health tips

    Additional Health Resources